Novel curcumin analogue hybrids: Synthesis and anticancer activity

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Biochemistry

Background:

• Thioredoxin reductase (TrxR) is a key enzyme in cellular redox balance and a potential target for cancer therapy.
• Curcumin analogues offer a promising scaffold for developing novel anticancer agents.
• Understanding the molecular mechanisms of action is crucial for drug development.

Purpose of the Study:

• To design and synthesize novel curcumin analogue hybrids as potential anticancer agents targeting TrxR.
• To evaluate the anticancer activity of these compounds against gastric cancer cells.
• To elucidate the molecular mechanisms underlying the anticancer effects of the most potent compound.

Main Methods:

• Design and synthesis of twenty curcumin analogue hybrids.
• In vitro anticancer activity assays using gastric cancer cell lines.
• Cell cycle analysis, mitochondrial function assessment, and TrxR activity inhibition assays.
• Western blot analysis to investigate protein expression changes (Bax/Bcl-2 ratio, TrxR oxidation).
• Exploration of reactive oxygen species (ROS) mediated signaling pathways (ASK1/MAPK).

Main Results:

• Compound 7d demonstrated significant anticancer activity, inducing apoptosis in gastric cancer cells.
• Compound 7d arrested the cell cycle, disrupted mitochondrial function, and inhibited TrxR activity.
• Western blot analysis showed increased Bax/Bcl-2 ratio and TrxR oxidation upon treatment with compound 7d.
• Preliminary evidence suggests compound 7d activates ROS-mediated ASK1/MAPK signaling pathways.

Conclusions:

• Compound 7d is a potent anticancer agent with a promising mechanism of action involving TrxR inhibition and ROS-mediated signaling.
• The designed curcumin analogues represent a valuable class of compounds for further investigation in gastric cancer therapy.
• Targeting TrxR and modulating ROS signaling are effective strategies for inducing cancer cell apoptosis.